“Increasing Focus on Disease-Modifying Therapies”
- One prominent trend in the global Alzheimer's therapeutics market is the increasing focus on disease-modifying therapies (DMTs) that aim to slow or halt the progression of Alzheimer’s disease
- These therapies target the underlying biological processes of the disease, such as amyloid plaques and tau tangles, offering hope for more effective treatments beyond symptomatic relief
- For instance, Aduhelm, developed by Biogen, is one of the first FDA-approved DMTs that targets amyloid beta plaques, a hallmark of Alzheimer’s, offering potential disease-modifying effects and sparking interest in other similar treatments
- In addition, advancements in biomarker development are enabling earlier diagnosis and more personalized treatment approaches, allowing therapies to be administered at the most beneficial stages of the disease
- This trend is reshaping the Alzheimer’s treatment landscape, with increased investment in research and development of innovative drugs aimed at slowing or preventing disease progression, which is fueling the market's growth and demand for new therapeutic options
